Consequently, when looking for a CG with favorable characteristics for the treatment of a brain disorder, key objectives would be to achieve low bioavailability in the heart, free concentrations in the brain that exceed levels required for NKA target engagement, and to select a CG that does not suppress the steady-state protein levels of any of the predominant NKA α subunits by more than 50%. Here, TAC1 is linked to brain disorder.